Compare iShares Core S&P 500 ETF (IVV) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core S&P 500 ETF vs Regeneron Pharmaceuticals Inc — how do they compare? iShares Core S&P 500 ETF trades at $782.01 (market cap $897.20B), while Regeneron Pharmaceuticals Inc trades at $746.12 (market cap $76.14B). The key difference: iShares Core S&P 500 ETF is far larger — about 11.8× Regeneron Pharmaceuticals Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while iShares Core S&P 500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core S&P 500 ETF for 46 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| IVV | REGN | |
|---|---|---|
Market Cap | $897.20B | $76.14B |
Volume | 4,580,672 | 500,239 |
Sector | Broad Market / Factor | Health |
52-Week High | $782.58 | $852.03 |
52-Week Low | $634.93 | $557.73 |
Typical Hold Time | 46 Days | 107 Days |
Enterprise Value | — | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IVV, tracking the S&P 500, trades at $782.06, up 0.19% with a bullish technical signal from moving averages. The ETF shows neutral oscillator readings with RSI at 68.88 suggesting mild overbought conditions. Recent news highlights S&P 500 valuation debates, with earnings growth expected to slow from 35% in 2026 to 15% in 2027 according to Wall Street analysts (24/7 Wall Street, 2026-10-03).
The outlook remains cautiously optimistic with seasonal patterns favoring year-end rallies, though concentration risks in top holdings and slowing profit growth present headwinds. Key support at $775 and resistance at $780 will dictate near-term direction as investors monitor economic data and Federal Reserve policy.
Regeneron Pharmaceuticals (REGN) trades at $747.21, up 0.69% with strong recent earnings beats. The stock shows bearish technical signals but maintains robust fundamentals with 84.86% gross margins and consistent revenue growth. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, providing significant upfront and milestone payments. Analyst consensus remains strongly bullish with 69% buy ratings and an $849.84 price target, representing 13.7% upside potential from current levels.
REGN presents a compelling growth story with strong profitability and strategic partnerships, though technical indicators suggest near-term consolidation. The expanded Sanofi collaboration and promising clinical trial data provide catalysts, while competition in key therapeutic areas and reliance on blockbuster drugs represent ongoing risks. Wall Street optimism remains high given the company's execution track record and pipeline potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
